OCTAPHARMA
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1983-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.octapharma.com/
Clinical Trials
73
Trial Phases
5 Phases
Drug Approvals
27
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (56 trials with phase data)• Click on a phase to view related trials
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
- Conditions
- HypogammaglobulinemiaAutoimmune ConditionsRheumatic ConditionsInfections
- Interventions
- Drug: Panzyga, 10% Intravenous SolutionOther: Placebo
- First Posted Date
- 2025-10-24
- Last Posted Date
- 2025-10-24
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 360
- Registration Number
- NCT07220915
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
- Conditions
- Significant Bleeding RiskVitamin K-Dependent Coagulation Defect
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 3574
- Registration Number
- NCT06429787
- Locations
- 🇺🇸
Octapharma Research Site, Boston, Massachusetts, United States
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 124
- Registration Number
- NCT06361537
- Locations
- 🇺🇦
Octapharma Research Site, Lviv, Ukraine
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
- Conditions
- Acquired Antithrombin Deficiency (Heparin Resistance)
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Octapharma AG
- Target Recruit Count
- 58
- Registration Number
- 2023-507560-39-00
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-11-13
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 28
- Registration Number
- NCT05936580
- Locations
- 🇨🇭
Insel Spital Bern, Bern, Switzerland
🇺🇾Centro Hospitalario Pereira Rossell, Montevideo, Uruguay
🇺🇸UT Health San Antonio, San Antonio, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
University of Colorado Launches $29 Million EFFECT Trial to Evaluate Early Fibrinogen Replacement in Trauma Care
The University of Colorado Anschutz Medical Campus received a $29 million grant from Octapharma to lead the EFFECT Trial, evaluating early fibrinogen replacement in trauma patients with life-threatening bleeding.
Octapharma's PANZYGA Shows Mixed Results in Phase 3 PANS Trial, Achieves Significant Secondary Endpoint
Octapharma's phase 3 trial of PANZYGA for pediatric acute-onset neuropsychiatric syndrome (PANS) missed its primary endpoint of reducing obsessive-compulsive symptoms measured by CY-BOCS score.